Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash & Current Investments: 2022-2024

Historic Cash & Current Investments for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $531.7 million.

  • Day One Biopharmaceuticals' Cash & Current Investments fell 19.13% to $451.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 19.00%. This contributed to the annual value of $531.7 million for FY2024, which is 45.14% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Cash & Current Investments of $531.7 million as of FY2024, which was up 45.14% from $366.3 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Cash & Current Investments registered a high of $531.7 million during FY2024, and its lowest value of $342.3 million during FY2022.
  • For the 3-year period, Day One Biopharmaceuticals' Cash & Current Investments averaged around $413.4 million, with its median value being $366.3 million (2023).
  • Data for Day One Biopharmaceuticals' Cash & Current Investments shows a peak YoY spiked of 45.14% (in 2024) over the last 5 years.
  • Over the past 3 years, Day One Biopharmaceuticals' Cash & Current Investments (Yearly) stood at $342.3 million in 2022, then grew by 7.03% to $366.3 million in 2023, then skyrocketed by 45.14% to $531.7 million in 2024.